Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158363 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29547181 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL2288397 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29792115 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29362301 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL21192401 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL5967470 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29401280 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31614333 | 0.94 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355931-B1 | PROTEIN CONJUGATES | NOVO NORDISK AS (DK) | 2024-06-26 | — | — | EP | disclosed |
| CN-106139158-B | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4303213-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377759-A | Self-purified nucleic acid-encoded libraries | 约尔格·谢尔曼 | 2024-01-09 | — | — | CN | disclosed |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4116306-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-2323694-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011015649-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-02-10 | — | — | WO | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| WO-2010015668-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | WO | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1858538-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-0989136-A1 | PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | DAO, ALAD, BCAT1 | MDM2 2670/4885MDM4 3845/4885TP53 4035/4885 |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | ALB, TFRC, FABP2 | MDM2 717/4885MDM4 1173/4885TP53 209/4885 |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | PSMA2, PSMA1, PSMA3 | MDM2 191/4885MDM4 386/4885TP53 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.